Related Experiment Video
Updated: Sep 28, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
[Pneumococcal meningitis and resistant bacteria]
1Service d'urgence et réanimation pédiatriques, hôpital Edouard-Herriot, place d'Arsonval 69437 Lyon, Lyon, France. daniel.floret@chu-lyon.fr
Abstract:
The emergence of resistance has imposed a modification of the protocols for the treatment of Streptococcus pneumoniae (S pneumoniae) bacterial meningitis. Amoxicillin is no longer adapted. As resistance to C3G appeared, a synergistic effect of an association C3G + vancomycine was demonstrated. Thus currently this association should be recommended in any case of meningitis supposedly due to S pneumoniae. The treatment is then modified according to the evolution and the minimal inhibition concentration (MIC) of the bacteria. The strains carrying a high level of resistance to cephalosporin (MIC > or = 4 micrograms ml-1) or tolerant to vancomycine may cause a therapeutic failure despite an increase of the dosage of cephalosporin. Rifampicin, fosfomycine, or imipenem (despite its risk of convulsions), may represent alternative options, as long as we do not have safe quinolones active on resistant strains of S. pneumoniae. Dexamethasone has been formerly implicated in the relapse of pneumococcal meningitis. Furthermore, its use is questionable since no evidence of a therapeutic benefit has been clearly demonstrated. As a consequence of the resistance phenomenon the management of S. pneumoniae meningitis must include particular measures: at least resistance to penicillin must be checked by the oxacilline disk and the MIC to C3G must be measured by E test; aCSF sample should be obtained between 36 and 48 hours following the beginning of the treatment to check its sterilization. All recent studies have shown a similar prognosis of meningitis due to resistant S. pneumoniae as compared to those due to sensitive strains. However, these data should be interpreted with caution since in these studies, pneumococcus resistant to cephalosporin (the real problem) are not separated from those only resistant to penicillin. Furthermore, presently, the incidence of strains highly resistant to cephalosporin is still low. The new conjugated vaccine against pneumococcus should change the situation if its ability to prevent the circulation of resistant strains is confirmed.
Insights
Bacterial meningitis treatment protocols are changing due to Streptococcus pneumoniae resistance. A combination of C3G and vancomycin is now recommended for S. pneumoniae meningitis, with treatment adjusted based on bacterial susceptibility.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Context:
- Emerging antibiotic resistance in Streptococcus pneumoniae necessitates updated treatment guidelines for bacterial meningitis.
- Traditional therapies like amoxicillin are becoming less effective.
- The appearance of resistance to third-generation cephalosporins (C3G) requires alternative therapeutic strategies.
Purpose:
- To review and recommend updated treatment protocols for Streptococcus pneumoniae meningitis in light of increasing antimicrobial resistance.
- To evaluate the efficacy of combination therapies and alternative agents.
- To highlight essential monitoring and diagnostic measures.
Summary:
- Amoxicillin is no longer a suitable primary treatment for S. pneumoniae meningitis.
- A combination of C3G and vancomycin demonstrates synergistic effects and is recommended for suspected S. pneumoniae meningitis.
- Treatment adjustments are based on bacterial minimum inhibitory concentration (MIC) and clinical response. Alternative options include rifampicin, fosfomycin, or imipenem.
- Monitoring includes oxacillin disk testing for penicillin resistance, C3G MIC measurement, and cerebrospinal fluid (CSF) sterilization checks.
Impact:
- The recommended C3G and vancomycin combination aims to improve therapeutic outcomes in resistant meningitis cases.
- Careful patient monitoring and susceptibility testing are crucial for successful treatment and preventing therapeutic failure.
- The development of new vaccines and quinolones may further alter the management landscape of resistant pneumococcal meningitis.
More Related Videos
06:06Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43
Published on: September 11, 2020
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
Related Concept Videos
Mechanism of Antibiotic Resistance in MRSA
Bacterial Meningitis II: Pathophysiology
Pneumonia I: Introduction
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Atypical Pneumonia
Bacterial Meningitis